Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Semler Scientific, Inc. filings document its common-stock status, material events and public-company reporting history. Recent regulatory records include Form 25 disclosure for removal of the common stock from Nasdaq listing and registration, and Form 15 certification covering termination or suspension of Exchange Act reporting obligations for the class of securities.
The company's 8-K filings cover material agreements, shareholder voting matters, governance items, capital-structure disclosures and operating and financial results. Filing categories also address risk factors and clinical or regulatory matters tied to Semler Scientific's healthcare technology activities, alongside disclosures related to its Bitcoin treasury strategy.
Strive, Inc. released a Rule 425 communication about its proposed business combination with Semler Scientific, Inc.. The message, posted by Strive’s CEO on X, emphasizes forward-looking statement cautions and states Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction. Semler Scientific stockholders will receive an Information Statement/Proxy Statement/Prospectus to vote on the deal. The notice reiterates that this is not an offer or solicitation.
Strive, Inc. posted a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in connection with the transaction.
A combined information statement, proxy statement, and prospectus will be sent to Semler stockholders to seek approval. Investors are urged to read these materials when available on the SEC’s website. The notice includes forward‑looking statement cautions and a clear no‑offer or solicitation disclaimer.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific. Strive plans to file a Form S-4 to register Class A common stock to be issued, which will include an information statement/proxy statement/prospectus.
A definitive proxy will be sent to Semler stockholders to seek approval. The communication includes forward-looking statements and clarifies it is not an offer or solicitation to sell securities.
Strive, Inc. posted a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The notice states Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. The communication emphasizes forward‑looking statement cautions and clarifies it is not an offer to sell or solicit the purchase of securities. Documents will be available on the SEC’s website and the companies’ investor sites.
Strive, Inc. filed a communication under Rule 425 about its proposed business combination with Semler Scientific, Inc. (SMLR). The notice includes a forward‑looking statements disclaimer and outlines required SEC materials.
Strive intends to file a Form S-4 to register the Class A common stock to be issued in the transaction. An Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The document also identifies potential solicitation participants and explains how investors can access SEC filings.
Semler Scientific (SMLR) and Strive, Inc. filed a Form 425 communication tied to their proposed business combination. The notice, reposted on X by Strive’s Chief Legal Officer, contains forward-looking statements and cautions about related risks. Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive definitive materials to vote on the deal. Documents will be available on the SEC website and the companies’ investor sites. This is not an offer to sell securities.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement/proxy statement/prospectus.
Semler Scientific stockholders will receive definitive materials to vote on the proposed transaction. The notice includes cautionary forward-looking statements and clarifies it is not an offer or solicitation to sell securities.
Strive, Inc. reposted a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus for Semler stockholders.
A definitive proxy will be sent to Semler stockholders to seek approval. Related documents will be available free on the SEC’s website and the companies’ investor sites. The notice emphasizes forward-looking statement risks and clarifies this is not an offer to sell or solicit any security.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive intends to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, and a combined information statement/proxy statement/prospectus will be sent to Semler stockholders to seek their approval.
The notice includes standard forward‑looking statements, identifies potential solicitation participants, and states this is not an offer or solicitation to buy or sell securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, with an Information Statement/Proxy Statement/Prospectus to be sent to Semler Scientific stockholders to seek their approval. The communication includes forward-looking statement cautions and directs investors to the SEC’s website and the companies’ investor pages for the Registration Statement and related materials when available.